


Stabilis



Carboplatin



Товарное название

Acoplastic	Мексика
Axicarb	Германия
Balidon	Колумбия
Blastocarb	Колумбия, Мексика, Перу, чили
Boplatex	Колумбия, Мексика, Эквадор
Carbip	Мексика
Carbodex	Турция
Carboeen	Индия
Carbokebir	Аргентина
Carbokem	Индия
Carbol	Перу
Carbomedac	Швеция
Carboplat	Аргентина, Германия, Мексика
Carboplatin	Австралия, Австрия, Бельгия, Бразилия, Греция, Дания, Египет, Индия, Иран, Ирландия, Исландия, Канада, Люксембург, Марокко, новая Зеландия, Саудовская Аравия, Соединённые Штаты Америки, Финляндия
Carboplatine	Марокко, Франция, Швейцария
Carboplatino	Аргентина, Испания, Колумбия, чили
Carbosin	Бельгия, Греция, Египет, Малайзия
Cycloplatin	Венгрия, Польша
Emorzym	Греция
Megaplatin	Греция
Nuvaplast	Мексика
Paraplatin	Австрия, Бельгия, Великобритания, Венгрия, Голландия, Греция, Дания, Испания, Италия, Люксембург, Мексика, Норвегия, Объединенные Арабские Эмираты, Польша, Соединённые Штаты Америки, Финляндия, Швейцария, Швеция
Paraplatine	Марокко, Тунис, Франция
Platinwas	Испания



Стабильность растворов

		3.2 mg/ml	25°C		30			2244
PVC		1 mg/ml	37°C		14			484
PVC		1 mg/ml	4°C		14			484
PVC		0,25 mg/ml	2-8°C		3			3830
PVC		0,25 mg/ml	25°C		24			3830
PVC		2 mg/ml	2-8°C		7			3830
PVC		2 mg/ml	25°C		24			3830
PVC		4 mg/ml	2-8°C		7			3830
PVC		4 mg/ml	25°C		2			3830
PVC		0,5 mg/ml	2-8°C		7			3341
PVC		0,5 mg/ml	25°C		7			3341
PVC		0,5 & 4 mg/ml	25°C		21			486
PVC		0,5 & 4 mg/ml	4°C		21			486
PVC		1 mg/ml	22°C		28			166
PVC		1 mg/ml	35°C		28			166
PVC		1 mg/ml	4°C		28			166
PVC		2,4 mg/ml	20°C-24°C		9			164
PVC		2.15 mg/ml	4°C		84			2203
PVC		5 mg/ml	2-8°C		7			3341
PVC		5 mg/ml	25°C		7			3341
PVC		6 mg/ml	37°C		14			1734
PVC		10 mg/ml	37°C		14			1734
PE		0,72 mg/ml	21-22°C		72			1520
PE		3.2 mg/ml	25°C		30			2244
PP		0,2 mg/ml	20-25°C		24			4120
PP		3.2 mg/ml	25°C		30			2244
POF		0.7 & 2.15 mg/ml	4°C		84			2203
POF		2 mg/ml	2-8°C		84			3670
EVA		1 mg/ml	22°C		28			166
EVA		1 mg/ml	35°C		28			166

EVA		1 mg/ml	4°C		28			166
PI		10 mg/ml	37°C		24			645
PI		10 mg/ml	4°C		120			645
PI		10 mg/ml	25°C		8			1667
PI		1 mg/ml	22°C		28			166
PI		1 mg/ml	35°C		28			166
PI		1 mg/ml	4°C		28			166



Стабильность смесей

		0,5 mg/ml	20°C-23°C		Granisetron hydrochloride : 0,5 mg/ml	4		57
		2 mg/ml	25°C		Acetyl L-carnitine : 15 mg/ml	4		3277
		2,5 mg/ml	?		Palonosetron hydrochloride : 25 µg/ml	4		1950
POF		2 mg/ml	23°C		Paclitaxel : 0,3 & 1,2 mg/ml	24		872
POF		2 mg/ml	32°C		Paclitaxel : 0,3 & 1,2 mg/ml	24		872
POF		2 mg/ml	4°C		Paclitaxel : 0,3 & 1,2 mg/ml	24		872
POF		2 mg/ml	23°C		Paclitaxel : 0,3 & 1,2 mg/ml	24		872
POF		2 mg/ml	32°C		Paclitaxel : 0,3 & 1,2 mg/ml	24		872
POF		2 mg/ml	4°C		Paclitaxel : 0,3 & 1,2 mg/ml	24		872
		0,45 mg/ml	20°C-23°C		Topotecan : 0,028 mg/ml	4		1026
		0,45 mg/ml	20°C-23°C		Topotecan : 0,028 mg/ml	4		1026



Факторы, которые влияют на стабильность

				2242
				2243
				2245
				3286
				3743
				409
				3341
				3830
				2254
				2253

					3830
					4205



Совместимость

		Carboplatin : 5 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Carboplatin		4965
		Carboplatin : 5 mg/ml		301
		Carboplatin : 5 mg/ml		1415
		Carboplatin		4965
		Carboplatin : 5 mg/ml Allopurinol sodium : 3 mg/ml		307
		Carboplatin : 1 mg/ml Amifostine : 10 mg/ml		3
		Carboplatin : 5 mg/ml Amifostine : 10 mg/ml		3
		Carboplatin : 5 mg/ml Amphotericin B cholesteryl sulfate complex : 0,83 mg/ml		921
		Carboplatin : 5 mg/ml Aztreonam : 40 mg/ml		99
		Carboplatin : 5 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Carboplatin : 5 mg/ml Cladribine : 0.5 mg/ml		1496
		Carboplatin : 5 mg/ml Doripenem : 5 mg/ml		2262
		Carboplatin : 5 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Carboplatin		409
		Carboplatin : 5 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Carboplatin : 5 mg/ml Filgrastim : 30 µg/ml		244
		Carboplatin : 5 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Carboplatin : 5 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Carboplatin : 5 mg/ml Linezolid : 2 mg/ml		1925
		Carboplatin : 5 mg/ml Micafungin : 1.5 mg/ml		2108
		Carboplatin : 0,18 >> 9,9 mg/ml Ondansetron hydrochloride : 0,016 >> 0,16 mg/ml		3574

		Carboplatin : 5 mg/ml Paclitaxel : 1.2 mg/ml		85
		Carboplatin : 2 mg/ml Paclitaxel : 0,3 & 1,2 mg/ml		872
		Carboplatin : 5 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Carboplatin : 5 mg/ml Propofol : 10 mg/ml		300
		Carboplatin : 5 mg/ml Teniposide : 0.1 mg/ml		905
		Carboplatin : 5 mg/ml Thiotepa : 1 mg/ml		249
		Carboplatin : 0.9 mg/ml Topotecan : 0.056 mg/ml		1026
		Carboplatin		3341
		Carboplatin : 5 mg/ml Cladribine : 0.015 mg/ml		1496
		Carboplatin : 5 mg/ml Doripenem : 5 mg/ml		2262
		Carboplatin Fluorouracil		3474
		Carboplatin : 100 mg/ml Fluorouracil : 1000 mg/ml		163
		Carboplatin : 5 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Carboplatin : 1 mg/ml Granisetron hydrochloride : 1 mg/ml		57
		Carboplatin : 5 mg/ml Melfalan : 0.1 mg/ml		169
		Carboplatin Mesna		3602
		Carboplatin : 5 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Carboplatin : 5 mg/ml Oxaliplatin : 0,5 mg/ml		1662
		Carboplatin : 2 mg/ml Paclitaxel : 0,3 & 1,2 mg/ml		872
		Carboplatin : 2.5 mg/ml Paclitaxel albumin : 5 mg/ml		4310
		Carboplatin : 5 mg/ml Palonosetron hydrochloride : 50 µg/ml		1950
		Carboplatin : 5 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Carboplatin : 5 mg/ml Sargramostim : 10 µg/ml		335
		Carboplatin : 0.9 mg/ml Topotecan : 0.056 mg/ml		1026
		Carboplatin : 5 mg/ml Vinorelbine tartrate : 1 mg/ml		84



Библиография

	ТИП	публикация
3	Журнал	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
57	Журнал	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	Журнал	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Журнал	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	Журнал	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
99	Журнал	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
163	Журнал	Sewell GJ, Allsopp M, Collinson MP, Tyrrell C, Prentice AJ, Copplestone JA. Stability studies on admixtures of 5-fluorouracil with carboplatin and 5-fluorouracil with heparin for administration in continuous infusion regimens. J Clin Pharm Ther 1994 ; 19: 127-133.
164	Журнал	Benaji B, Dine T, Luyckx M, Brunet C, Goudaliez F, Mallevais ML, Cazin M, Gressier B, Cazin JC. Stability and compatibility of cisplatin and carboplatin with PVC infusion bags. J Clin Pharm Ther 1994 ; 19: 95-100.
166	Журнал	Rochard E, Barthes D, Courtois P. Stability and compatibility study of carboplatin with three portable infusion pump reservoirs. Int J Pharm 1994 ; 101: 257-262.
169	Журнал	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
244	Журнал	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Журнал	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.

251	Журнал	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300	Журнал	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Журнал	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Журнал	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Журнал	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Журнал	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
409	Журнал	Cheung YW, Cradock JC, Vishnuvajjala BR, Flora KP. Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm 1987 ; 44: 124-130.
484	Журнал	Northcott M, Allsopp MA, Powell H, Sewell GJ. The stability of carboplatin, diamorphine, 5-fluorouracil and mitozantrone infusions in an ambulatory pump under storage and prolonged "in use" conditions. J Clin Pharm Ther 1991 ; 16: 123-129.
486	Журнал	Diaz Amador F, Sevilla Azzati E, Herreros de Tajeda y Lopez-Coterilla A. Stability of carboplatin in polyvinyl chloride bags. Am J Health-Syst Pharm 1998 ; 55: 602, 604.
492	Журнал	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
645	Журнал	Sewell GJ, Riley CM, Rowland CG. The stability of carboplatin in ambulatory continuous infusion regimes. J Clin Pharm Ther 1987 ; 12: 427-432.
872	Журнал	Zhang YP, Xu QA, Trissel LA, Gilbert DL, Martinez F. Compatibility and stability of paclitaxel combined with cisplatin and with carboplatin in infusion solutions. Ann Pharmacotherapy 1997 ; 31: 1465-1470.
905	Журнал	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Журнал	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1026	Журнал	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1410	Журнал	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.

1415	Журнал	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Журнал	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Журнал	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1520	Лаборатория	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1625	Журнал	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Журнал	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1667	Журнал	Valière C, Arnaud P, Caroff E, Dauphin JF, Clément G, Brion F. Stability and compatibility study of a carboplatin solution in syringes for continuous ambulatory infusion. Int J Pharm 1996 ; 138: 125-128.
1734	Журнал	Hadfield JA, McGown AT, Dawson MJ, Thatcher N, Fox BW. The suitability of carboplatin solutions for 14-day continuous infusion by ambulatory pump : an HPLC-dynamic FAB study. J Pharm Biomed Anal 1993 ; 11: 723-727.
1925	Журнал	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1950	Журнал	Trissel LA, Yanping Z. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration. J Oncol Pharm Practice 2004 ; 10: 191-195.
1953	Журнал	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Журнал	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2108	Журнал	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2203	Журнал	Kaestner S, Sewell G. A sequential temperature cycling study for the investigation of carboplatin infusion stability to facilitate 'dose-banding'. J Oncol Pharm Practice 2007 ; 13: 119-126.
2242	Журнал	Lederer M, Leipzig-Pagani E. A note on the solution chemistry of carboplatin in aqueous solutions. Int J Pharm 1998 ; 167, 1-2: 223-228.
2243	Журнал	Pujol M, Girona V, Prat J, Munoz M, De Bolos J. Degradation pathway of carboplatin in aqueous solution. Int J Pharm 1997 ; 146: 263-269.

2244	Журнал	Prat J, Pujol M, Girona V, Munoz M, Sol? L-A. Stability of carboplatin in 5% glucose solution in glass, polyethylene and polypropylene containers. J Pharm Biomed Anal 1994 ; 12, 1: 81-84.
2245	Журнал	Torres F, Girona V, Puil M, Prat J, de Bolos J. Stability of carboplatin in 5% glucose solution exposed to light. Int J Pharm 1996 ; 129: 275-277.
2247	Журнал	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2253	Журнал	Curis E, Provost K, Bouvet D, Nicolis I, Crauste-manciet S, Brossard D, B?nazeth S. Carboplatin and oxaliplatin decomposition in chloride medium, monitored by XAS. J Synchrotron Rad 2001 ; 8: 716-718.
2254	Журнал	Curis E, Provost K, Nicolis I, Bouvet D, B?nazeth S, Crauste-Manciet S, Brion F, Brossard D. Carboplatin decomposition in aqueous solution with chloride ions monitored by X-ray absorption spectroscopy. New J Chem 2000 ; 24: 1003-1008.
2262	Журнал	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3277	Журнал	Yang Z, Cameron S, Paul H. Stability of Carboplatin, Paclitaxel, and Docetaxel with Acetyl-L-carnitine During Simulated Y-site Administration. Int J Pharm Compound 2012 ; 16, 1 : 82-85.
3286	Журнал	Okamoto Y, Tazumi K, Sanada Y, Tsugane M, Uejima E. Light-induced Deterioration Test of Carboplatin under Clinical Settings. Yakugaku Zasshi 2010 ; 130, 10: 1369-1374.
3341	Журнал	Trittler R, Jung B, Strehl E. Ist teurer immer auch besser? Analytiklabor der Apotheke unterstützt Einkauf sentcheidungen bei Carboplatin-Präparaten. Krankenhauspharmazie 2001 ; 7: 331-333.
3474	Лаборатория	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3574	Лаборатория	Ondansetron - Résumé des caractéristiques du produit Accord Healthcare France SAS 2013
3602	Лаборатория	Mesna (Uromitexan®)- Summary of Product Characteristics Baxter SAS 2013
3670	Журнал	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3743	Журнал	Allsopp M.A, Sewell G.J, Rowland C.G, Riley C.M, Schowen R.L. The degradation of carboplatin in aqueous solutions containing chloride or other selected nucleophiles. Int J Pharm 1991 ; 69: 197-210.
3830	Журнал	Myers A.Ls, Zhang Y-P, Kawedia L, Trinh V.A, Tran H, Smith J.A, Kramer M.A. Stability study of carboplatin infusion solutions in 0.9% sodium chloride in polyvinyl chloride bags. J Oncol Pharm Practice 2016 ; 22: 31-36.
4120	Журнал	Vazquez-Sanchez R, Sanchez-Rubio-Ferrandez J, Cordoba-Diaz D, Cordoba-Diaz M, Molina-Garcia T. Stability of carboplatin infusion solutions used in desensitization protocol. J Oncol Pharm Practice 2018 25,5:1076?1081
4205	Журнал	Choi S, O La H, Kim K, Kim S, Hwangbo S. Stability of Carboplatin in normal saline : dependence on initial dilution concentration and storage time. J Kor Soc Hosp Pharm 2006 ;23,3:219-224
4310	Журнал	Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, Yano I, Minami H, Hiral M. Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs. Kaohsiung J Med Sci 2017 ; 63, 1: E9-E16.

4965	Лаборатория	CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion - Résumé des caractéristiques du produit. ACCORD HEALTHCARE FRANCE SAS 2025
------	-------------	--



Словарь

	Цитостатическое средство		Инъекция
	Товарное название		Стабильность растворов
	Упаковка		Молекула Molekula
	Концентрация		Температура
	Хранение		Продолжительность стабильности
	биоподобие		противоречивые данные
	Ссылки		Стекло
	Глюкоза 5%		Защищён от света
	День		Поливинилхлорид
	Вода для инъекций		Натрия хлорид 0,9%
	Свет		Час
	Нет		Полиэтилен
	Не указано		Полипропилен
	Полиолефин		Этилен-винилацетат
	Шприц полипропилен		Полиизопреновый эластомер
	Стабильность смесей		Растворитель
	Молекула		Не указано
	Факторы, которые влияют на стабильность		Стимулирует
	Деградация		Пониженная стабильность
	Повышение, увеличение		Пониженная концентрация
	Совместимость		совместимый
	Парентеральное питание (бинарная смесь)		Парентеральное питание (с липидами)
	Немедленная мутность		несовместимый
	NaCl 0,9% + антибактериальный		Осадки через 4 часа
	Химическая нестабильность		Неопределенная несовместимость
	Способы введения		Интравенная, внутривенная инфузия
	Библиография		Словарь